coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Updates in Medicine | CagriSema

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

Our physicians are board-certified in obesity medicine, with additional board certifications across relevant specialties

The Retatrutide and Tesamorelin stack delivers 25-30% weight loss while preserving muscle

This powerful combination []